Catherine L. B.
- Country
- France
- Department
- Hepatogastroenterology
Research Overview
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- A Study to Test How Well Obefazimod Works and How Safe It Is for Patients with Moderately to Severely Active Ulcerative Colitis
- Efficacy and Safety of Obefazimod for Induction in Adults with Moderately to Severely Active Ulcerative Colitis: Randomized, Double‑Blind, Placebo‑Controlled III Trial
Data & Insights
Has run more than one trial at 43 of 146 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in treating inflammatory bowel diseases, with particular focus on ulcerative colitis and Crohn's disease.
- Moderate to Severe Ulcerative Colitis Management
- Crohn's Disease Therapeutics
- Bowel Urgency Assessment
The investigator evaluates novel therapeutic approaches for inflammatory bowel conditions.
Therapeutic Innovation
The research focuses on investigating emerging treatments including obefazimod and mirikizumab for gastrointestinal disorders.
- Novel Drug Evaluation
- Treatment Response Assessment
- Long-term Therapeutic Outcomes
Special attention is given to endoscopic improvement and symptomatic remission in chronic inflammatory conditions.
Clinical Outcomes
The investigator studies clinical remission and disease maintenance in gastrointestinal disorders.
- Endoscopic Improvement Analysis
- Symptomatic Relief Assessment
- Long-term Safety Monitoring
Research encompasses both short-term therapeutic efficacy and extended treatment outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.